Premium
Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.
Author(s) -
Drohse A,
Bathum L,
Brosen K,
Gram LF
Publication year - 1989
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1989.tb03426.x
Subject(s) - mephenytoin , sparteine , urine , debrisoquine , pharmacogenetics , pedigree chart , polymorphism (computer science) , biology , genetics , chemistry , allele , endocrinology , genotype , stereochemistry , gene
The oxidation of mephenytoin was polymorphic in 358 healthy Danish volunteers. The ratio between the chromatographic peak areas of (S)‐ and (R)‐mephenytoin (S/R) in 12 h urine was less than or equal to 0.48 in 349 extensive metabolizers (EM) and greater than or equal to 1 in 9 (2.5%) poor metabolizers (PM). Concomitant intake of mephenytoin and sparteine and subsequent assay by gas chromatography had no influence on the test results (mephenytoin S/R ratio or sparteine metabolic ratio). Among ten parents and seven siblings to six unrelated PM of mephenytoin only one (1/17 = 5.9%) was a PM. The pedigrees were compatible with an autosomal recessive mode of inheritance.